A case of Baló concentric sclerosis: a fulminant variant of multiple sclerosis?

2026

Full text Open access: Hybrid Metadata (CSL-JSON)
DOI 10.66636/gmj.v1.i3.a180
Data confidence 85 high
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Modern research into Baló concentric sclerosis has revealed a characteristic neuroradiological picture, while clinical manifestations range widely, including benign and malignant forms of demyelinating disease. Immunological diagnostics remain poorly characterised. We report a 17-year-old Caucasian male from Kazakhstan who initially presented to the emergency department with acute focal neurological deficits, including right-sided hemiparesis and gait unsteadiness, mimicking acute ischaemic stroke. Brain magnetic resonance imaging revealed multifocal lesions in the thalamus, temporal, and parietal lobes with pronounced diffusion restriction, confirming Baló concentric sclerosis. Following high-dose intravenous methylprednisolone, rapid neurological improvement was observed. A subsequent relapse led to the diagnosis of relapsing-remitting multiple sclerosis, and disease-modifying therapy with ocrelizumab was initiated with a satisfactory response. This case demonstrates that Pattern I demyelination can underlie atypical variants evolving into classical multiple sclerosis, highlighting the need to combine neuroimaging with immunopathological profiling to predict disease trajectories. Keywords: Baló concentric sclerosis; multiple sclerosis; concentric ring lesions; demyelinating disease; ocrelizumab; corticosteroid treatment; case report